“Association of serum ɣ-Glutamyl transpeptidase levels with overall survival in Intermediate and Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization”

[1]  Lianxin Liu,et al.  Changes in the Epidemiology of Hepatocellular Carcinoma in Asia , 2022, Cancers.

[2]  M. Wholey,et al.  Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization , 2022, Cureus.

[3]  H. Tseng,et al.  Hepatocellular carcinoma surveillance: current practice and future directions , 2022, Hepatoma research.

[4]  Dimitrios Schizas,et al.  Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? , 2022, Journal of personalized medicine.

[5]  S. Sarin,et al.  Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study. , 2021, Journal of clinical and experimental hepatology.

[6]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[7]  Jianhai Guo,et al.  γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. , 2020, Journal of vascular and interventional radiology : JVIR.

[8]  B. Carr,et al.  Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantation , 2020, The International journal of biological markers.

[9]  S. Spiliopoulos,et al.  Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions , 2019, World journal of gastroenterology.

[10]  W. Liao,et al.  Prognostic Value of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in Patients With Single Tumor Size ≤ 5 cm Hepatocellular Carcinoma After Radical Resection , 2019, Front. Oncol..

[11]  H. El‐Serag,et al.  Epidemiology and Management of Hepatocellular Carcinoma. , 2019, Gastroenterology.

[12]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[13]  Y. Huang,et al.  The gamma‐glutamyl transpeptidase‐to‐albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients , 2017, Journal of viral hepatitis.

[14]  Zhen Shen,et al.  Prognostic significance of the pretreatment serum gamma-glutamyltransferase levels in Chinese patients with non-metastatic cervical cancer , 2017, Oncotarget.

[15]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[16]  Qiang Zhao,et al.  Elevated Preoperative Serum Gamma-glutamyltranspeptidase Predicts Poor Prognosis for Hepatocellular Carcinoma after Liver Transplantation , 2016, Scientific Reports.

[17]  I. Fentiman.  Gamma-glutamyl transferase: risk and prognosis of cancer , 2012, British Journal of Cancer.

[18]  N. Concin,et al.  Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial , 2012, British Journal of Cancer.

[19]  N. Concin,et al.  Relevance of gamma-glutamyltransferase--a marker for apoptotic balance--in predicting tumor stage and prognosis in cervical cancer. , 2011, Gynecologic oncology.

[20]  S. Ye,et al.  Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization , 2011, European journal of gastroenterology & hepatology.

[21]  A. Corti,et al.  Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. , 2009, Anticancer research.

[22]  Aldo Paolicchi,et al.  Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance , 2006 .

[23]  J. Whitfield.  Gamma Glutamyl Transferase , 2001, Critical reviews in clinical laboratory sciences.

[24]  M. Burt,et al.  Elevation of glutathione and related enzyme activities in high-grade and metastatic extremity soft tissue sarcoma , 1997, Annals of Surgical Oncology.

[25]  K. H. A..  The Serum Gamma Glutamyl Transpeptidase - A Non invasive Diagnostic Bio Marker of Chronic Anicteric Non Alcoholic Liver Diseases. , 2013, Journal of clinical and diagnostic research : JCDR.

[26]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.